Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/17214
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHall, Victoria-
dc.contributor.authorKwong, Jason-
dc.contributor.authorJohnson, Douglas F-
dc.contributor.authorEkinci, Elif I-
dc.date2017-
dc.date.accessioned2018-03-12T21:52:46Z-
dc.date.available2018-03-12T21:52:46Z-
dc.date.issued2017-05-22-
dc.identifier.citationBMJ Case Reports 2017; 2017: bcr-2017-219335en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/17214-
dc.description.abstractWe describe an adverse outcome in a 70-year-old man with type 2 diabetes mellitus treated with sodium-glucose cotransporter type 2 (SGLT2) inhibitor dapagliflozin. SGLT2 inhibitors act in the proximal tubules to prevent glucose reabsorption and induce urinary glucose excretion, they have been associated with increased risk of urinary tract infection (UTI). Our patient presented to hospital withEscherichia colisepticaemia with positive urine and blood cultures on the background of two previous UTIs occurring post commencement of dapagliflozin in the community. Renal tract ultrasound in hospital revealed incomplete bladder emptying with evidence of urinary stasis, and a postvoid residual volume of 180 mL. His dapagliflozin was ceased, and he has had no further episodes of UTI. This case suggests there may be an increased risk of UTI in patients prescribed SGLT2 inhibitors who also have evidence of bladder outlet obstruction-caution is advised in the prescribing of SGLT2 inhibitors in this setting.en_US
dc.language.isoeng-
dc.subjectContraindications and precautionsen_US
dc.subjectEndocrine systemen_US
dc.subjectInfectionsen_US
dc.subjectUrinary and genital tract disordersen_US
dc.subjectUrinary tract infectionsen_US
dc.titleCaution advised with dapagliflozin in the setting of male urinary tract outlet obstruction.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleBMJ Case Reportsen_US
dc.identifier.affiliationGeneral Medicineen_US
dc.identifier.affiliationInfectious Diseasesen_US
dc.identifier.affiliationEndocrinologyen_US
dc.identifier.affiliationMedicine (University of Melbourne)en_US
dc.identifier.doi10.1136/bcr-2017-219335en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0003-2372-395Xen_US
dc.identifier.pubmedid28536217-
dc.type.austinCase Reports-
dc.type.austinJournal Article-
dc.type.austinCase Report-
local.name.researcherEkinci, Elif I
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptEndocrinology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

24
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.